In a phase 3 trial, more deaths due to adverse events were reported in the Trodelvy arm compared with the chemotherapy arm. Gilead has made the decision to withdraw the accelerated approval of ...

Complementary advances in molecular imaging and targeted therapeutics for urothelial cancer are providing new opportunities for more effective personalized treatment. Tumor-specific positron emission ...

Adjuvant pembrolizumab more than doubled disease-free survival (DFS) after radical surgery in patients with high-risk muscle-invasive urothelial cancer, according to new findings from the phase 3 ...

Circulating tumor DNA (ctDNA) is an emerging technology that is rapidly transforming the management of patients with cancer -- not only in hematologic malignancies, but increasingly also in solid ...

Enfortumab vedotin showed a robust disease control rate in patients with urothelial cancer outside of a clinical trial, and its efficacy was not inferior in patients with diabetes and/or neuropathy.

Fibroblast growth factor receptor 3 (FGFR3) alteration status and outcomes with immune checkpoint inhibitors (ICPI) in patients with metastatic urothelial carcinoma. This is an ASCO Meeting Abstract ...

A statistically significant improvement in overall survival was observed with the combination vs platinum-based chemotherapy. The Food and Drug Administration (FDA) approved Keytruda ® (pembrolizumab) ...

A confirmed objective response rate of 68.2% and a disease control rate of 95.5% was observed with Daiichi Sankyo and AstraZeneca’s DATROWAY in combination with rilvegostomig in previously untreated, ...

- Visugromab demonstrated potent and durable clinical efficacy as well as excellent tolerability in combination with nivolumab in advanced-stage/last-line non-small cell lung cancer (NSCLC) and ...

Nearly 20,000 women are diagnosed with bladder cancer each year, according to the American Cancer Society, with most being ...